Want to see SE:SPEC full AI Analyst Report?

SpectraCure AB (SPEC) Price & Analysis

1 Followers

SPEC Stock Chart & Stats

kr0.18

kr0.10(5.82%)

At close: Mar 06 4:00 PM EST

kr0.18

kr0.10(5.82%)

Day’s Range― - ―

52-Week Rangekr0.02 - kr0.24

Previous CloseN/A

Volume60.95K

Average Volume (3M)8.80M

Market Cap

kr29.81M

Enterprise Valuekr39.03

Total Cash (Recent Filing)kr7.63M

Total Debt (Recent Filing)kr8.91M

Price to Earnings (P/E)―

Beta-0.10

Next Earnings

Nov 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding1,426,541,500

10 Day Avg. Volume9,292,544

30 Day Avg. Volume8,798,124

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.68

Price to Sales (P/S)0.00

P/FCF Ratio-1.46

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Financial LeverageVery low leverage limits debt-related financial risk and preserves flexibility compared with a highly indebted medtech company. This gives SpectraCure more room to pursue clinical development and commercialization without a large interest burden, although it does not offset operating losses.

Targeted Minimally Invasive PlatformA minimally invasive treatment platform with real-time monitoring is a differentiated clinical proposition that may support adoption if trials and regulatory work are successful. Targeted therapy can also help SpectraCure establish a focused position in prostate cancer treatment and related clinical applications.

Recurring Procedure-linked Revenue PotentialCombining capital equipment with procedure-related consumables could create a recurring revenue component after systems are installed at clinics. If clinical adoption develops, consumable use may increase with treatment volume and make the model more durable than relying only on infrequent equipment sales.

Bears Say

No Current RevenueThe absence of reported revenue indicates that SpectraCure has not yet demonstrated commercial traction or a functioning revenue base. This leaves future performance dependent on clinical adoption, regulatory clearances, reimbursement, and deployment of the platform, making near-term operating visibility structurally weak.

Persistent And Widening LossesLarge and widening operating and net losses show that the business remains in a heavy investment phase without evidence of operating leverage. Continued unprofitability can consume capital before commercialization scales, reducing the company’s ability to fund development and absorb delays in market adoption.

Sustained Cash BurnNegative operating and free cash flow mean the company is not currently self-funding its operations. Persistent burn increases reliance on cash reserves or external funding to continue development and commercialization, which can constrain strategic choices and create financing pressure over the next several quarters.

SPEC FAQ

What was SpectraCure AB’s price range in the past 12 months?

SpectraCure AB lowest stock price was kr0.02 and its highest was kr0.24 in the past 12 months.

What is SpectraCure AB’s market cap?

SpectraCure AB’s market cap is kr29.81M.

When is SpectraCure AB’s upcoming earnings report date?

SpectraCure AB’s upcoming earnings report date is Nov 13, 2026 which is in 55 days.

How were SpectraCure AB’s earnings last quarter?

SpectraCure AB released its earnings results on Aug 21, 2026. The company reported -kr0.008 earnings per share for the quarter.

Is SpectraCure AB overvalued?

According to Wall Street analysts SpectraCure AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SpectraCure AB pay dividends?

SpectraCure AB does not currently pay dividends.

What is SpectraCure AB’s EPS estimate?

SpectraCure AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SpectraCure AB have?

SpectraCure AB has 1,426,541,500 shares outstanding.

What happened to SpectraCure AB’s price movement after its last earnings report?

SpectraCure AB reported an EPS of -kr0.008 in its last earnings report. Following the earnings report the stock price went up 5.405%.

Which hedge fund is a major shareholder of SpectraCure AB?

Currently, no hedge funds are holding shares in SE:SPEC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SpectraCure AB

SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT) system. This cutting-edge system is currently in Phase II clinical trials, where its efficacy in addressing solid tumors is being evaluated. The Swedish company, established in Lund in 2003, continues to advance its therapeutic solutions.